The biotechnology R&D intensity in Norway's business sector is projected to increase modestly from 0.022 in 2024 and 2025 to 0.023 in 2026, and continuing its growth trend to 0.024 in 2027 and 0.025 in 2028. Judging by the continuous upward trajectory, this forecast points to a gradual but steady commitment to innovation within the industry.
Year-on-year variations are minimal between 2024 and 2025, holding steady at 0%, but begin to increase incrementally from 2026 onwards, exhibiting a 4.5% increase from 2026 to 2027 and another 4.2% increase from 2027 to 2028. This results in a Compound Annual Growth Rate (CAGR) of approximately 2.65% from 2024 to 2028. This steady growth is indicative of an industry starting to increase its investment in biotechnology R&D.
Trends to watch for include the impact of government policies, enterprise innovation strategies, and international collaborations which could accelerate the R&D intensity further. Additionally, advancements in related sectors such as pharmaceuticals, agriculture, and environmental management could significantly influence these forecasts.
